The FDA has approved updates toSusvimo, which will be available to U.S. retina specialists and patients with wet AMD in the coming weeks.
Susvimo offers the first alternative to regular eye injections that are standard of care for wet AMD, which impacts 1.5 million people in the U.S. and 20 million people worldwide and can cause blindness if left untreated
By continuously delivering medicine to the eye through a refillable implant, Susvimo is the first and only approved wet AMD treatment shown to maintain vision with two refills a year. - Full Article
Ask your OD Liaison for more information!
Unsure who your OD Liaison is? We are here to help!
Please call our Director of Sales & Marketing, Lisa Good at 630-833-9621 x131.
